Brucellosis is a contagious disease caused by brucella. It is transmitted from carrier animals to susceptible people through multiple transmission methods. It is a common disease in clinical. The currently recommended anti-brucella regimens include double and triple antibacterial combination consisting of doxycycline, rifampicin, quinolone drugs and aminoglycosides and so on. But the failure rate and relapse rate are still high. Tigecycline and minocycline as tetracyclines can be selected as candidates. Brucella is sensitive to both drugs in vitro experiments. Fifty percent minimal inhibitory concentration (MIC50) and 90% minimum inhibitory concentration (MIC90) of the two drugs were low. Clinical studies have also confirmed that combined antibacterial regimens containing tigecycline and minocycline have lower failure rate and relapse rate. Therefore, tigecycline and minocycline can be candidates for the treatment of brucellosis.